Success Metrics

Clinical Success Rate
100.0%

Based on 11 completed trials

Completion Rate
100%(11/11)
Active Trials
13(42%)
Results Posted
91%(10 trials)

Phase Distribution

Ph phase_2
18
58%
Ph phase_3
7
23%
Ph not_applicable
1
3%
Ph phase_1
3
10%

Phase Distribution

3

Early Stage

18

Mid Stage

7

Late Stage

Phase Distribution29 total trials
Phase 1Safety & dosage
3(10.3%)
Phase 2Efficacy & side effects
18(62.1%)
Phase 3Large-scale testing
7(24.1%)
N/ANon-phased studies
1(3.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

91.7%

11 of 12 finished

Non-Completion Rate

8.3%

1 ended early

Currently Active

13

trials recruiting

Total Trials

31

all time

Status Distribution
Active(16)
Completed(11)
Terminated(1)
Other(3)

Detailed Status

Completed11
Recruiting7
Active, not recruiting6
unknown3
Not yet recruiting3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
31
Active
13
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (10.3%)
Phase 218 (62.1%)
Phase 37 (24.1%)
N/A1 (3.4%)

Trials by Status

completed1135%
recruiting723%
withdrawn13%
unknown310%
active_not_recruiting619%
not_yet_recruiting310%

Recent Activity

Clinical Trials (31)

Showing 20 of 31 trialsScroll for more
NCT05873192Phase 2

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Recruiting
NCT05059236Phase 2

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

Active Not Recruiting
NCT04523207Phase 2

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

Completed
NCT07538843

An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment

Not Yet Recruiting
NCT05794906Phase 3

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

Active Not Recruiting
NCT06592924Phase 3

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Recruiting
NCT06235697Phase 3

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

Recruiting
NCT07450599Phase 2

A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.

Not Yet Recruiting
NCT05849298Phase 2

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Active Not Recruiting
NCT04633252Phase 1

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

Recruiting
NCT03496805Phase 2

Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy

Completed
NCT04720157Phase 3

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Active Not Recruiting
NCT03388619Phase 1

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

Completed
NCT07210086Phase 2

Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)

Recruiting
NCT07344779

A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice

Not Yet Recruiting
NCT06060587Phase 2

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

Withdrawn
NCT02972060Phase 2

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

Active Not Recruiting
NCT05555017Phase 2

Tracer-Guided Surgery for Recurrent Prostate Cancer

Unknown
NCT00268476Phase 2

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

Active Not Recruiting
NCT05406999Phase 2

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
31